ASR Vermogensbeheer N.V. Sells 2,320 Shares of Moderna, Inc. $MRNA

ASR Vermogensbeheer N.V. decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 10.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 19,327 shares of the company’s stock after selling 2,320 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Moderna were worth $533,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Invesco Ltd. increased its position in shares of Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after buying an additional 877,162 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Moderna by 0.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company’s stock valued at $101,982,000 after buying an additional 11,270 shares in the last quarter. Northern Trust Corp increased its position in shares of Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company’s stock valued at $88,441,000 after buying an additional 160,572 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after buying an additional 285,662 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Moderna by 1.8% in the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock valued at $54,382,000 after buying an additional 34,034 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $28.49 on Friday. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $62.11. The company has a market capitalization of $11.08 billion, a P/E ratio of -3.78 and a beta of 2.01. The company has a 50-day simple moving average of $26.30 and a 200 day simple moving average of $27.37.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. During the same period last year, the business posted ($3.33) EPS. Moderna’s revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on MRNA. Wells Fargo & Company restated an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Moderna in a research report on Saturday, September 27th. Leerink Partners lowered their target price on Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a report on Friday, August 22nd. Barclays lowered their target price on Moderna from $40.00 to $31.00 and set an “equal weight” rating for the company in a report on Monday, August 4th. Finally, JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have assigned a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $41.81.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.